C
andidemia is the most frequent invasive fungal infection in pediatric patients, but remains a rare disease as indicated by the few previous population-based studies. Annual incidence rates have been reported in the range of 0.81-10.5/1000 admissions in single-and multihospital studies. [1] [2] [3] [4] Incidence rates from populationbased studies also vary extensively but are consistently higher for infants (<1 year) than noninfants with rates in infants ranging from 6.9 to 96.4/100,000 live births. [5] [6] [7] [8] [9] [10] [11] The diverging incidence rates call for further insights into clinical characteristics of pediatric candidemia. For instance, it is not clear whether changes in species distribution towards nonalbicans species have taken place in children as well as in adults. 12 Most studies have been limited to well-recognized risk groups such as patients in neonatal intensive care units (ICUs) and patients with hematologic diseases. Population-based studies describing clinical characteristics of pediatric candidemia patients are sparse.
We aimed to investigate incidence, species distribution, underlying diseases, patient management and outcome by age and time in a nationwide cohort study of pediatric candidemia patients during an 11-year period.
METHODS AND MATERIALS

Health Care System
The Danish health care system is tax financed and divided into 5 health regions. Children up to the 15 years of age are admitted to pediatric departments. Treatment guidelines distinguish between pediatric and adult patients.
Study Population
The Danish population increased from 5,397,640 to 5,627,235 during the study period. Candidemia patients were identified through the national reference mycology laboratory and completeness was ensured in collaboration with all departments of clinical microbiology as previously described. 13, 14 Collaboration with local pediatricians was established for review of patient charts as instructed by the National Health Authorities. Data were collected using structured questionnaires in Research Electronic Data Capture (REDCAP, Vanderbilt University), a secure web-based application hosted at Aarhus University. prior infection, heart malformations, hematologic diseases [malignancies (n = 30), hemophagocytic lymphohistiocytosis (n = 1), aplastic anemia (n = 2)], solid cancers, hepatobiliary disorders and others, (2) treatment regimens; use of central venous catheter (CVC), chemotherapy, corticosteroids, mechanical ventilation, total parenteral nutrition (TPN) and surgery, (3) antifungal treatment (AFT); compound, date of initiation and termination, (4) stay in ICU and (5) information on length of hospital stay (Supplemental Table 1 ; http://links.lww.com/INF/D307). Optimal AFT upon species identification was assessed according to susceptibility classification (EUCAST). 16 Microbiologic data on blood cultures and colonization (examinations of colonization performed 7 days before to 3 days after candidemia) were collected from the laboratory information systems. Date of death was obtained from patient charts up until the date of data collection yielding minimum 2 years of follow-up for all patients; the local clinicians evaluated if death was attributable to candidemia, or not possible to assess. Change or removal of CVC was calculated among patients with CVC and surviving ≥2 days for CVC removal/change to be possible.
For the clinical evaluation, patients were categorized as neonates (≤28 days of age), infants (29 days to 2 years) and older children (3-15 years).
Ethics
Ethical permission for data collection was obtained from the Danish Health authorities (journal no 3-3013-1427/1/) and the Danish Data Protection Agency (journal no 2007-58-0010).
Statistical Analyses
Incidence rates were calculated for all candidemia patients, and separately for neonates (<28 days), infants (<1 year) and noninfants (1-15 years) using denominators for corresponding years obtained from Statistics Denmark (http://www.statistikbanken.dk). Incidence rates for neonates were calculated by dividing the number of candidemias in neonates with the total number of live births. When calculating incidence rates for infants the denominator included neonates because it was not possible to separate neonates from the population of ≤1-year-old infants obtained from Statistics Denmark.
In line with previous studies we categorized age as neonates (≤28 days of age), infants (29 days to 2 years) and older children (3-15 years) to describe and compare clinical characteristics and outcomes across age. 2, 3 For each age group, we summarized continuous variables by median and interquartile range (IQR) and reported numbers and proportions for discrete variables. To assess changes over time, the study period was divided: 2004 to 2009 and 2010 to 2014. χ 2 test was used for categorical data and Fisher exact test for variables with less than 10 observations. Venn diagrams were used to visualize the distribution of underlying diseases according to age group using "Venn Diagram Maker online." 17 Patients were followed from the collection date for the positive blood culture and we assessed all-cause mortality at day 2, 14 and 30. In these analyses, only first-time episodes of candidemia were included to preserve the assumption of independent observations. Statistical analyses were performed with Stata, v. 14 (StataCorp, US).
RESULTS
Patients and Incidence Rates
From January 2004 to December 2014, 153 pediatric patients with 158 episodes of candidemia were identified (Fig. 1) . One episode was poly-fungal and 5 children had 2 episodes of candidemia. Clinical data was available for 91.8% (145/158) of all candidemia episodes of which 24.1% (35/145) were neonates, 39.3% (57/145) were infants and 36.6% (53/145) were older children. The median age for nonneonatal patients (29 days to 15 years) were 2 years (IQR: 0-6 years).
The annual number of patients varied from 12 episodes in 2005 and 2012 to 18 in 2009 with the majority of patients (93.1%, 147/158) being admitted at 1 of the 4 large university hospitals at the time of diagnosis. The overall annual incidence rate for candidemia episodes was 1.3/100,000 population, whereas the agespecific annual incidence rate varied from 10.2/100,000 population for children <1 year of age to 0.8/100,000 population for children 1-15 years of age (Fig. 2) . The annual incidence rate for neonates was 5.7/100,000 live births; in LBW neonates it was 103.8/100,000 LBW births. Overall, the incidence remained stable over time ( Fig. 2A) .
Species Distribution
The species distribution and proportion of isolates with fluconazole resistance differed by age group and study period ( 
Patient Characteristics and Underlying Diseases
Most patients were males (58.2%), although the male dominance decreased with increasing age (Table 1) . ICU stay, sepsis, TPN and mechanical ventilation were most prevalent among neonatal patients and decreased with increasing age (Table 1) . Conversely, body temperature and C-reactive protein were lower among neonates compared with older patients, as were the proportion of patients with CVC (Table 1) . Removal or change of CVCs was performed in the majority of patients and slightly more frequently among the neonatal patients (88.2%). Four-fifths of nonneonatal patients had prior hospital contact before the current admission with candidemia in contrast to one-third of neonatal patients (80.2% vs. 32.4%). Surgery within the prior 30 days was most frequent among infants compared with neonates and older patients (44.2%) ( Table 1) . Virtually all patients had at least 1 underlying disease (98.6%) and with a considerable overlap between the underlying diseases (Fig. 3) . Multimorbidity (defined as 2 or more underlying diseases) was present in 43.5% of patients, the highest proportion of multimorbidity was found among the older children (47.2% vs. 42.9% in neonates and 40.4% in infants). The diversity of underlying diseases was highest among nonneonatal patients (Fig. 3) . Prematurity was common among the neonates (71.4% were born before a gestational age of 32 weeks), and all preterm neonates had LBW (76.0% had a birth weight <1000g). The most frequent underlying disease for infants was gastrointestinal disease (35.1%), for older children it was hematologic disease (39.6%). Heart malformations were especially prevalent in the 2 youngest age groups (22.9% in neonates and 12.3% in infants). The proportion of solid cancers and hematologic disease increased with age (none in neonates, 12.3% and 21.1% in infants, 18.9% and 39.6% in older children, respectively). Patients with hematologic diseases were distinct with regard to species distribution as less than half had C.
albicans candidemia (C. albicans 48.5%), and a larger proportion had fluconazole resistant species compared with nonhematologic disease patients (27.3% vs. 6.3%, P = 0.002).
AFT
One-fourth of all patients had received AFT within 7 days prior to the blood culture positive for candida was obtained. This proportion 2-3 doubled with age (Table 2) . Prior AFT was given daily in all but 1 patient, and for more than 7 days in 11% (2.7% of neonates, 12.0% of infants and 17.7% of older children). Prior AFT was most prevalent among patients with hematologic disease (63.5% and 39.4% with ≥7 day's duration). Seven or more days of prior AFT was associated with higher proportion of nonalbicans species (80.0%), whereas the species distribution was comparable among patients with less than 7 days prior AFT (16.7% nonalbicans) and AFT naive patients (26.2% nonalbicans) (P = 0.000, nonalbicans vs. C. albicans in all 3 groups). Prior AFT was also associated with subsequent fluconazole resistant species compared with no prior AFT (27.3% vs. 4.9%, P = 0.001). The proportion of fluconazole resistant species was greater in patients with ≥7 days duration of prior AFT compared with <7 days duration and no prior AFT (40.0% vs. 18.5% and 5.8%, P = 0.001).
The majority of children received AFT after blood culture collection (88.2%). Neonatal patients and older children most commonly received azoles (42.9% and 39.2%), whereas infants most commonly received amphotericin B (40.0%). Initial AFT was optimal for the majority of treated patients (95.8%) with no difference by age. www.pidj.com | 467
Outcome
The overall 30-day mortality was 10.2%, and for all timepoints highest among neonates and lowest among infants (Table 1) . Mortality was not associated with choice of AFT and numbers were too small to adjust for underlying diseases. The overall 30-day mortality was considered attributable to candidemia in 5 deaths (35.7%), unrelated to candidemia in 5 deaths (35.7%), whereas in 4 deaths (28.6%) it was not possible to assess the cause of death. Ninety-day mortality was 15.3% (21/137). Seven patients died from day 30-90; 5 of these deaths (71.4%) were assed as attributable to candidemia and 2 deaths (28.6%) as "unrelated to candidemia." Thus, indicating an overall attributable mortality of 3.7% at day 30 and 7.3% at day 90.
The overall 30-day mortality for primary candidemia increased from 6. 0%) . B, Fifty-seven patients 1 month to 2 years of age: gastrointestinal disease (35.1%); prior infection (22.8%); hematologic disease (21.1%); very preterm (14.0%); solid cancer (12.3%); heart malformations (12.3%); hepatobiliary disorders (7.0%); other (7.0%); burns (3.5%). C, Fifty-three patients 3-15 years of age: hematologic disease (39.6%), prior infection (32.1%), solid cancer (18.9%), neurologic disease (18.9%), gastrointestinal disease (13.2%), hepatobiliary disease (9.4%), other (9.4%), heart malformations (7.6%).
DISCUSSION
This nationwide pediatric candidemia cohort study showed a stable incidence during 2004 to 2014. The incidence was substantially higher in neonates, and 10 times higher in LBW neonates. C. albicans was the predominant species, although the proportion declined over time and with prior AFT for ≥7 days duration. Fluconazole resistance increased over time, in particular among the older children. Virtually all children had at least 1 underlying disease; most neonates were immature and acutely ill. Gastrointestinal disease and recent surgery was frequent in infants, whereas older children had solid cancers or hematologic disease. Heart malformations and gastrointestinal disease were identified as important risk factors in neonates and infants. Choice of AFT varied across age groups but the proportion with optimal treatment was consistently high regardless of age. Overall 30-day mortality was 10.2%, highest among neonates (17.1%) and increasing over time.
The incidence rate of 0.8/100,000 population among children 1-15 years of age is comparable with rates reported in previous studies (0.25-2.6/100,000 population). [5] [6] [7] 9, 11, 18 Conversely, the incidence of 10.2/100,000 population for infants <1 year was higher than reported in our neighboring countries Finland and Norway (6.9 and 7.5/100,000 population), 5, 7 but markedly lower than in other population-based studies (15.7-96.4/100,000 population). 6, [8] [9] [10] [11] A considerable decline in incidence rates from 52.1/100,000 population in 2009 to 15.7/100,000 in 2015 was observed in a study from the United States. 11 An improvement in infection control precautions was suggested to have caused the decline. The low and stable Danish incidence rate for children contrasts the high incidence rates for adult candidemia, suggesting genetic predisposition is not an important cause of the latter. 12, 19 Despite the notable decline in incidence rates in the US study, the rate reported for neonates remained twice as high as in our study (10.7 vs. 5.7/100,000 population), whereas an Australian study reported similar incidence rate for neonates of 4.4/100,000 population. 18 We are unaware of other reports of population-based incidence rates for neonates. Our study extends these findings by providing estimates for LBW infants in a nationwide perspective. Further comparisons could be valuable to clarify what drives the high incidence among infants as well as the large national difference.
In line with our findings, a recent US study also showed a decline in C. albicans with increasing age. 11 The proportion of C. parapsilosis varies by setting and age, and was low in our setting (13.3%) compared with estimates from Australia (38%-42%), 18 Latin America (27%), 4 Taiwan (27%) 20 and Turkey (22%). 2 This may suggest appropriate infection control practices, as C. parapsilosis is the species most commonly found on the skin and associated with device infections. 21 The increasing fluconazole resistance over time has not previously been reported among children. We demonstrated that fluconazole resistance was associated with use of antifungal prophylaxis and hematologic disease. This underlines the importance of monitoring species distribution and resistance and to adjust treatment guidelines according to local epidemiology.
Our finding that neonatal patients were acutely ill with a high proportion of ICU admission, mechanical ventilation, sepsis and TPN while older children most frequently had hematologic diseases and solid cancers is in concordance with previous studies. 4, 11, 18 The high burden of multimorbidity have not previously been recognized and illustrates the heterogeneity of the pediatric candidemia population, and furthermore identify the underlying diseases for each age group. Heart malformations and gastrointestinal disease were identified as common underlying diseases with few other studies focusing on these diseases. An international study from 2007 to 2011 with 196 pediatric patients found 16% with gastrointestinal disease, 22 whereas an Australian study from 2001 to 2004 with 142 pediatric patients found zero cases with gastrointestinal disease among neonates and 9.1% among nonneonate pediatric patients. 18 Congenital heart disease was found among 11% in a single center study from United States, 3 heart valve disorders and cardiomyopathy together accounted for 12.6% in a US study with 192 candidemia patients. 23 The high proportion of patients who presented with gastrointestinal disease or heart malformations in the current study, as well as gastrointestinal disease being an established risk factor among adult candidemia patients warrants further investigation.
The proportion of patients receiving prior AFT was comparable to previous studies (10.7%-36%). 3, 11, 20, 23 In line with what has been reported for adults, 24 prior AFT for ≥7 days was associated with higher prevalence of nonalbicans species. Furthermore, prior AFT was associated with higher proportion of fluconazole resistance in subsequent species. To our knowledge, this has not previously been reported for children and underlines the importance of addressing prior AFT in children and of local surveillance programs.
Data on mortality of pediatric candidemia is sparse and often not age-specific. The 30-day mortality of 10.2% is in line with estimates of previous studies (10%-18%), 1,2,11 except from the high BCC indicates blood culture collection.
